Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa
Publication date
2002-08
Authors
van de Vijver, D.R.E.
Roos, R A C
Jansen, Pascal W T C
Porsius, A
De Boer, Anthonius
Editors
Advisors
Supervisors
DOI
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
AIMS: We determined whether the start of selective serotonin reuptake inhibitors (SSRI) in levodopa users was followed by a faster increase of antiparkinsonian drug treatment. METHODS: Selected were all levodopa users of 55 years and older from the PHARMO prescription database. The rate of increase of antiparkinsonian drug treatment was compared using Cox's proportional hazard model for starters of SSRI (n = 15) with starters of tricyclic antidepressants (TCA) (n = 31) and with patients not using antidepressants (n = 304), and was adjusted for age, gender, and duration of levodopa use. RESULTS: The hazard ratio for the SSRI group compared with the TCA group was 4.2 (95% confidence interval 1.4, 12.6) and compared with the second control group was 2.7 (1.2, 5.2). CONCLUSIONS: The start of SSRI therapy in levodopa users is followed by a faster increase of antiparkinsonian drug treatment.
Keywords
Econometric and Statistical Methods: General, Geneeskunde (GENK), Farmacie/Biofarmaceutische wetenschappen (FARM), Epidemiology, Farmacie(FARM), Geneeskunde(GENK), Bescherming en bevordering van de menselijke gezondheid, Biomedische technologie en medicijnen, Ziekenhuisstructuur en organisatie van de gezondheidszorg, Public Health, Internal medicine, SDG 3 - Good Health and Well-being
Citation
van de Vijver, D A M C, Roos, R A C, Jansen, P A F, Porsius, A J & de Boer, A 2002, 'Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa', British Journal of Clinical Pharmacology, vol. 54, no. 2, pp. 168-170.